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A B S T R A C T
The aim of this work was to profile, by using an HPLC-MS/MS method, cranberry compounds and metabolites
found in human urine after ingestion of a highly standardized cranberry extract (Anthocran®). Two different
strategies were adopted for the data analysis: a targeted and an untargeted approach. These strategies allowed
the identification of 42 analytes including cranberry components, known metabolites and metabolites hitherto
unreported in the literature, including six valerolactones/valeric acid derivatives whose presence in urine after
cranberry consumption has never been described before. Absolute concentrations of 26 over 42 metabolites were
obtained by using pure available standards. Urine collected at different time points after the last dosage of
Anthocran® were tested on the reference strain C. albicans SC5314, a biofilm-forming strain. Fractions collected
after 12 h were found to significantly reduce the adhesion and biofilm formation compared to the control
(p < 0.05). A similar effect was then obtained by using Anthocran™ Phytosome™, the lecithin formulation
containing 1/3 of standardized cranberry extract and formulated to enhance the absorption of the cranberry
components. The urinary profile of cranberry components and metabolites in the urine fractions collected at 1 h,
6 h and 12 h after the last capsule intake were then reproduced by using the pure standards at the concentration
ranges found in the urine fraction, and tested on C. albicans. Only the mixture mimicking the urinary fraction
collected at 12 h and containing as main components, quercetin and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
was found effective thus confirming the ex-vivo results.
1. Introduction
Candida albicans is one of the most common fungi causing disease in
humans and the most frequently isolated fungal pathogen in nosoco-
mial urinary tract infections (UTIs) [1,2]. Urological devices, urological
procedures, diabetes and being female are the main factors linked to
candiduria [3]. Catheters, which are used in up to 20% of hospitalized
subjects [4], represent an adhesion substrate for microorganisms that
can easily develop biofilm on plastic or silicone surfaces. The most
important feature of microbial biofilms is their tolerance to
antimicrobial therapies [5], leading to recurrent or persistent infec-
tions. Therefore, alternative approaches to conventional antifungal
therapy are desirable and among these the search of botanical products
provides opportunities for new therapeutic approaches.
Cranberry (Vaccinium macrocarpon) is a rich source of polyphenols,
which possess beneficial properties towards pathogenic infections in-
cluding urinary tract infections (UTIs), dental caries and stomach ulcers
[6]. Moreover, berry phenolics showed antioxidant, anti-inflammatory
and anticancer properties [7,8]. A synergy of all the phytochemicals
could explain the great health benefits of cranberry reported in in vitro
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studies [9–11]. Despite all these potential applications, thus far pre-
vention of UTIs remains the main application for cranberry based
products [12]. The major constituents of cranberry are flavonols, an-
thocyanins, proanthocyanidins (PACs), flavan-3-ols and phenolic acids
and derivatives [13]. Several in vitro studies have supported the hy-
pothesis that the antiadhesive properties of cranberry are due to PACs,
and in particular to the A-type [14]. However, controversial results
regarding their presence in human urine are reported: many in vivo
studies have demonstrated that they are not detected after cranberry
intake [15–19], but two works have shown their presence in urine at a
very low concentration [20,21]. The use of different dosages and non-
standardized cranberry products could explain these controversial re-
sults. The purpose of the present work is to profile the components and
metabolites in human urine after ingestion of a highly standardized
cranberry extract (Anthocran®, Indena S.p.A.) which has been found
effective in human studies [22–24]. Furthermore, the evaluation of the
activity of urinary fractions on C. albicans adhesion collected at dif-
ferent times following cranberry intake was performed. The quantita-
tive analysis of the metabolites identified in each urine fraction com-
bined with the urine activity on C. albicans adhesion has permitted the
identification of an array of compounds responsible for inhibiting
fungal adherence. Finally, the ex-vivo activity of Anthocran™ Phyto-
some™, lecithin formulation of the standardized cranberry extract was
tested in order to evaluate whether the lipid matrix can improve the
bioavailability and bioactivity of the extract.
2. Materials and methods
2.1. Reagents
Formic acid, ethyl gallate, protocatechuic acid, p-coumaric acid, gallic
acid, sinapinic acid, 2-hydroxybenzoic acid, 3-hydroxybenzoic acid, 4-
hydroxybenzoic acid, 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic
acid, 2,4-dihydroxybenzoic acid, 3-(4-hydroxyphenyl)-propionic acid, 3,4-
dihydroxyphenylacetic acid, hippuric acid, 3,4-dihydroxyhydrocinnamic
acid, 2-hydroxyhippuric acid, quinic acid, 2-methylhippuric acid, YPD
medium, Roswell Park Memorial Institute 1640 medium (RPMI), phos-
phate buffered saline (PBS), crystal violet, methanol and LC–MS grade
solvents were purchased from Merck KGaA, Darmstadt, Germany.
Kaempferol, quercetin, syringetin, quercetin-3-O-rhamnoside, quercetin-3-
O-galactoside were from Extrasynthese (Genay Cedex, France). Quercetin-
3-O-arabinofuranoside, 3-hydroxyhippuric acid and 4-hydroxyhippuric
acid were from Carbosynth (Compton Berkshire, UK). LC-grade H2O (18
MΩ cm) was prepared with a Milli-Q H2O purification system (Millipore,
Bedford, MA, USA). SPE Hypersep C18 column (100 mg/mL) were from
Thermo Scientific (Milan, Italy). Standardized cranberry extract (V. mac-
rocarpon) and the capsules containing 36 mg PACs/capsule (Anthocran®),
12 mg PACs/capsule Anthocran™ Phytosome™ and placebo capsule were
supplied by Indena S.p.A (Milan, Italy).
2.2. Synthesis of 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (I)
1H NMR spectra were recorded operating at 300 MHz while 13C
NMR at 75.43 MHz. Chemical shifts are reported in ppm relative to
residual solvent (CHCl3 or DMSO) as internal standard. Signal multi-
plicity is designed according to the following abbreviations: s = singlet,
d = doublet, dd = doublet of doublets, t = triplet, m = multiplet, br
s = broad singlet, br t = broad triplet. Purifications were performed by
flash chromatography using silica gel (particle size 40–63 μm, Merck)
on IsoleraTM (Biotage, Uppsala, Sweden) apparatus.
Palladium on carbon, 3,4-bis(benzyloxy)benzaldehyde, 2(5H)-fur-
anone, tert-butyldimethylsilyl trifluoromethanesulfonate (TBDMSOTf),
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), sodium bisulfite, 37% HCl,
cyclohexane, ethyl acetate, tetrahydrofuran, ethanol and methanol
were purchased from Merck KGaA, Darmstadt, Germany.
Compound I was afforded (Fig. 1) by Mukaiyama aldol addition
between 3,4-bis(benzyloxy)benzaldehyde (1) and 2(5H)-furanone (2)
in presence of tert-butyldimethylsilyl trifluoromethanesulfonate and
DBU. 5-(3′,4′-bis(benzyloxy)benzylidene)furan-2(5H)-one (3) was ob-
tained as a mixture of Z/E isomers (70:30). Reduction of 3 by H2 Pd/C
provided the final compound 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
(I) as racemic mixture.
5-(3′,4′-Bis(benzyloxy)benzylidene)furan-2(5H)-one (3). Under ni-
trogen atmosphere, DBU (0.28 mL, 1.88 mmol) was added dropwise to a
solution of 2 (158 mg, 1.88 mmol) in dry THF (16 mL). The mixture was
stirred for 30 min at room temperature. After cooled down to −10 °C tert-
butyldimethylsilyl trifluoromethanesulfonate (0.48 mL, 2.07 mmol) and 1
(600 mg, 1.88 mmol) were added dropwise and the mixture was stirred
1 h at −10 °C, then DBU (0.56 mL, 3.76 mmol) was added dropwise. The
reaction mixture was stirred overnight at room temperature, then solvent
was removed under vacuum. Ethyl acetate (20 mL), EtOH (5 mL) and
saturated solution of sodium bisulfite (5 mL) were added to the crude
residue and stirred overnight at 40 °C. The phases were separated and the
organic layer was diluted with ethyl acetate (15 mL), treated with 2.9 N
HCl (3 × 20 mL), washed with brine (20 mL), dried and concentrated to
afford a sticky black oil. The crude product was purified on silica gel
(75:25 cyclohexane/ethyl acetate) to afford the title compound as an
orange/brown oil (137 mg, 0.36 mmol, 19% yield).
1H NMR (300 MHz, CDCl3) Z isomer: δ = 7.53 (d, J = 7.0 Hz, 4H),
7.49 – 7.24 (m, 9H), 6.92 (d, J= 8.4 Hz, 1H), 6.15 (d, J= 5.3 Hz, 1H),
5.91 (s, 1H), 5.22 (s, 2H), 5.20 (s, 2H).
1H NMR (300 MHz, CDCl3) E isomer: δ = 7.53 (d, J = 7.0 Hz, 4H),
7.49 – 7.24 (m, 9H), 6.92 (d, J= 8.4 Hz, 1H), 6.21 (d, J= 5.3 Hz, 1H),
5.91 (s, 1H), 5.18 (s, 2H)), 5.14 (s, 2H).
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (I). 3 (275 mg, 0.72 mmol)
was dissolved in CH3OH (16.50 mL), and 3% Pd/C (40 mg) was added.
The reaction mixture was stirred overnight under hydrogen atmosphere
at room temperature, then the catalyst was removed by filtration. The
filtrate was concentrated in vacuo to afford the desired product as an
orange oil (125 mg, 0.60 mmol, 83% yield).
1H NMR (300 MHz, CD3OD) δ = 6.71 – 6.67 (m, 2H), 6.56 (dd,
J = 7.9, 2.2 Hz, 1H), 4.77 – 4.66 (m, 1H), 2.87 (dd, J = 14.1, 6.1 Hz,
1H), 2.78 (dd, J = 14.0, 6.1 Hz, 1H), 2.52 – 2.41 (m, 1H), 2.35 (dd,
J = 9.4, 4.7 Hz, 1H), 2.29–2.17 (m, 1H), 2.03 – 1.88 (m, 1H).
13C NMR (75 MHz, CD3OD) δ = 173.17, 144.88, 143.80, 127.60,
120.45, 116.20, 114.90, 81.86, 40.03, 28.14, 26.44.
2.3. Subject selection
A total of thirteen volunteers (mean age 25 ± 4 years and BMI
20.6 ± 2.0 kg m−2) were recruited from students and staff of the
Fig. 1. Synthesis of compound I – a) DBU, TBDMSOTf, THF dry, −10 °C; b) H2,
Pd/C, CH3OH, RT.
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University of Milan according to the following inclusion criteria:
women, 18–40 years of age, normal weight for height (18–25 kg m−2),
non-smokers, no history of cardiovascular, diabetes, hepatic, renal, or
gastrointestinal diseases. Subjects with allergy and/or aversion to
cranberry and/or cranberry products were excluded. Other exclusion
criteria were as follow: consumption of any dietary supplement, drug or
medication for at least one month before the beginning of the study.
The study was performed in accordance with the ethical standards es-
tablished in the 2013 Declaration of Helsinki and approved by the
Ethics Committee of the University of Milan (December 18, 2018, ref.
57/18). The study was registered at www.isrctn.org as
ISRCTN32556347. All participants signed an informed consent form.
2.4. Study design on healthy volunteers
Subjects were instructed to limit the consumption of polyphenols at
least 72 h before experimentation and during the trial. A list of foods to
be avoided has been provided to the volunteers. The list included: fruits
and vegetables rich in polyphenols (e.g. berries, red/purple fruits/ve-
getables), chocolate and some beverages such as coffee, tea, wine and
fruit juice. The study consisted of a randomized, double blind, 2-arm
repeated measure cross-over design. One group of subjects consumed 2
capsules of Anthocran® per day, while the other group 2 the capsules of
Anthocran™ Phytosome™ per day. The experiment was 7-day long.
Urine samples were collected before starting supplementation (day 1,
time 0) and after the last dosage (day 7) at the following time-points: 1,
2, 4, 6, 10, 12, 24 h. After one week of wash-out the groups inverted the
treatment. Each subject received a box containing the number of cap-
sules to consume during the experiment. Capsules were provided in a
blind condition. Subjects were instructed to swallow two capsules per
day, the first one in the morning before breakfast and the second one
before dinner with a glass of water. Three volunteers consumed two
placebo capsules with the same shape, size, colour, flavour and ex-
cipients of the products tested. Urine samples were collected at the
same time-points as previously reported and used as control to verify
the influence of diet and circadian rhythm on C. albicans activity. Ethyl
gallate 10 µM was added as internal standard in the sample used for the
MS analysis and all the samples were stored at −80 °C until analysis.
2.5. Sample preparation
An aliquot (1 mL) of each of the 10 subjects’ urine was centrifuged
at 10000 × g for 5 min and the supernatant was extracted on the SPE
column, working at 1 mL/min. Salts were removed with water and then
all the compounds retained were eluted with 1 mL 100% acetonitrile.
The fractions collected were dried under vacuum and then solubilized
in 100 µL H2O-CH3OH-HCOOH (90:10:0.1, v/v). For the quantitative
analysis, the stock solutions of the standards were prepared in methanol
and then diluted in a pool of the pre-treatment urine samples to obtain
the final concentrations for each calibration curve. The samples were
then added with ethyl gallate 10 µM as internal standard and processed
as described.
2.6. Chromatographic conditions
Cranberry components and urine metabolite separation was per-
formed on a reversed-phase Agilent Zorbax SB-C18 column
(150 × 2.1 mm, i.d. 3.5 µm, CPS analitica, Milan, Italy), protected by
an Agilent Zorbax guard column, kept at 40 °C, by an UltiMate 3000
system (Dionex) equipped with an autosampler kept at 4 °C working at
a constant flow rate (200 µL/min). Each sample (10 µL) was injected
into the column and both cranberry components and urine metabolites
were eluted with an 80 min multistep gradient of phase A H2O-HCOOH
(100:0.1, v/v) and phase B CH3CN-HCOOH (100:0.1, v/v): 0–45 min,
from 10% B to 20% B; 45–65 min, from 20% B to 60% B; 65–66 min,
from 60% B to 90% B; 66–70 min, isocratic of 90% B; 70–71 min, from
90% B to 10% B, and then 71–80 min of isocratic 10% B.
2.7. Polyphenol class identification by HPLC-UV analysis
The identification of polyphenol classes was carried out by HPLC-
UV analysis on a HPLC Surveyor LC system (Thermo Fisher Scientific,
Milan, Italy) equipped with a quaternary pump, UV–VIS detector (PDA)
and an autosampler. The scan range was set from 200 nm to 600 nm. A
solution of 4 mg/mL of cranberry extract in H2O/CH3OH/HCOOH (90/
10/0.1% v/v) was used for the analysis.
2.8. Cranberry component profiling and urine metabolite characterization
by high resolution mass spectrometry
Each sample (10 µL) was injected into the RP column as previously
described: the cranberry extract was analyzed at a concentration of
4 mg/mL in H2O-CH3OH-HCOOH (90:10:0.1, v/v), while the urine
samples were analyzed after the treatment described in section 2.3. The
analyses were performed on a LTQ-Orbitrap XL mass spectrometer
using an ESI source. Mass spectra were acquired in positive and in
negative ion modes. A list of 20 background ions was adopted as lock
mass values for real time mass calibration [25]. The source parameters
used for the positive mode are: spray voltage 4 kV, capillary tempera-
ture 300 °C, capillary voltage 30 V, tube lens offset 90 V; for the ne-
gative ion mode: spray voltage 4 kV, capillary temperature 300 °C,
capillary voltage −23 V, tube lens offset −140 V. The instrument was
set up to work in a data-dependent scan mode to acquire both full MS
and MS/MS spectra. Full MS spectra were acquired in profile mode by
the FT analyzer in a scan range of m/z 100–1200, using AGC scan target
5 × 105 and resolution 30,000 FWHM at m/z 400. Tandem mass
spectra were acquired by the linear ion trap (LTQ) which was set up to
fragment the 3 most intense ions exceeding 1 × 104 counts. Mass ac-
quisition settings were: centroid mode, AGC scan target 5 × 104, pre-
cursor ion isolation width of m/z 3, and collision energy (CID) of 35 eV.
Dynamic exclusion was enabled to reduce redundant spectra acquisi-
tion: 2 repeat counts, 20 sec repeat duration, 30 sec of exclusion
duration. Moreover, only singly and unassigned charged ions were
fragmented. Instrument control and spectra analysis were provided by
the software Xcalibur 2.0.7 and Chromeleon Xpress 6.80.
2.9. Targeted and untargeted analyses of cranberry components and
metabolites in human urine
An in-house database was created for the targeted analysis by
adding all the characterized cranberry extract components as well as
known cranberry metabolites identified in other studies and cranberry
components deriving from other cranberry sources even if not present
in the extract under investigation. The identification was carried out on
the QualBrowser tool of Xcalibur 2.0.7 by using the accurate mass and
the isotopic and fragmentation patterns.
The untargeted analysis consisted of searching for all the ions pre-
sent in the urine samples collected after the cranberry consumption that
were not present or present at intensity relative to noise (< 5*102
counts) in the pre-treatment sample. Spectra analyses were carried out
on the QualBrowser tool of Xcalibur 2.0.7 by screening the full MS
spectra acquired in negative ion mode in mass ranges of m/z 5 with
10 min as acquisition time for each sample. Each ion detected with
these filters was exported with the relative MS/MS spectrum, if present.
Identification was performed by following two different approaches
based on the accurate mass and isotopic and fragmentation patterns.
The first approach consists of giving the precursor ion and the MS/MS
spectrum list as inputs in the Compound Identification tool of CFM-ID
[26], using as mass tolerance error 10 ppm for the precursor ion and
0.3 Da for the fragments. CFM-ID performs a search for candidates in
available databases (HMDB and KEGG) based on the accurate mass,
then generating in-silico MS/MS spectra of all the candidates and then
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comparing the experimental data with those obtained in-silico. The top
candidates were ranked (Jaccard Score) according to how closely they
matched and returned to a list. The second approach was initially fo-
cused on the calculation of the elemental composition performed on the
Elemental Composition page of Xcalibur 2.0.7 by using the following
parameters: mass tolerance 10 ppm, charge −1, C, H, O, N, P, S as
elements in use. The top 5 formulae were searched in available data-
bases such as PubChem. METLIN, MassBank and in the literature in
order to obtain a list of candidates. Following this, the Peak Assignment
tool of CFM-ID was used to predict the MS/MS spectra of the putative
identified compounds and to compare the in-silico spectra obtained with
the experimental spectra.
2.10. Quantitative analysis
The calibration curves for each available metabolite were built by
plotting the peak area ratios of metabolite/ethyl gallate versus the
nominal concentrations of the metabolite by weighted (1/x2) least-
squares linear regression. Table 1 shows all the obtained linear curves
and the relative limit of quantification (LOQ). All the samples and ca-
libration solutions were analyzed in triplicates. The areas under the
curve of the extracted ion chromatogram of each identified metabolite
was integrated by using the Genesis peak algorithm of the Qual Browser
tool of Xcalibur 2.0.7.
2.11. Candida albicans biofilm formation assay
The biofilm-forming ability of C. albicans under various conditions
(i.e. medium supplementation with cranberry extract or urine fractions)
was evaluated on polystyrene 96-well plates using the reference strain
C. albicans SC5314 [27]. Prior to experiments, C. albicans was grown
overnight in yeast extract, peptone, dextrose (1% w/v yeast extract, 2%
w/v peptone, 2% w/v dextrose) broth (YPD) at 30 °C in an orbital
shaker. Cells were then harvested and washed with cold phosphate-
buffered saline (PBS) and counted by hemocytometer. A standard in-
oculum of 5 × 105 yeast cells/mL was prepared in Roswell Park
Memorial Institute 1640 medium (RPMI) and incubated in presence and
absence of urine fractions as well as in the presence of Anthocran™
0.1 mg/mL. 100 µL/well of the inoculum was firstly incubated at 37 °C
for 1 h to promote adhesion. Non-adherent cells were removed and
wells washed with PBS; medium was replaced and the plate further
incubated for 24 h. Biofilm-forming ability was quantified by crystal
violet (CV) staining for total biomass measurement [28]. Two in-
dependent experiments were carried out with six replicates for each
condition. The statistical analysis was performed by GraphPad Prism
6.02 for Windows, GraphPad Software, La Jolla California USA,
(www.graphpad.com) using the one-way ANOVA with Dunnet’s mul-
tiple comparisons test.
3. Results and discussion
3.1. Compliance
Volunteers confirmed the consumption of the capsules and the
compliance was also verified by counting the capsules in the returned
boxes. All the participants had 100% compliance and declared no ad-
verse effects following the intervention.
3.2. Characterization of Anthocran® components
Polyphenol classes of the cranberry extract were characterized by
HPLC-UV analysis at typical wavelength: 310–320 nm for phenolic
acids, 350–370 nm for flavonols, 520 nm for anthocyanins, 278 nm for
benzoic acids, flavanols and PACs. The identification of each compound
in the extract was then obtained on the basis of the accurate mass and of
the isotopic and the fragmentation patterns, by acquiring the mass
spectra in positive and in negative ion mode. All identified compounds
are reported in Table 2, Tables 3 and 4.
3.3. Targeted analysis of human urine after cranberry extract intake
The targeted analysis consisted of searching in the urine samples for
the compounds listed in an in-house database (total number of com-
pounds = 138), which comprises the cranberry extract components
characterized as reported in section 3.2 and cranberry compounds and
metabolites as reported elsewhere [15–21,29,30]. Identification was
Table 1
Calibration curve parameters for the available metabolites.
Metabolite [M−H]− Slope Intercept R2 Limit of Quantification (µM)
Protocatechuic acid 153.0189 0.1529 −0.04789 0.991 0.25
p-Coumaric acid 163.0408 0.2786 −0.03032 0.995 0.01
Gallic acid 169.0146 0.0253 −0.00585 0.991 1
Sinapinic acid 223.0608 0.0452 −0.00523 0.990 0.005
Kaempferol 285.0407 1.0160 0.07999 0.991 0.001
Quercetin 301.0353 1.1520 −0.05015 0.999 0.005
Syringetin 345.0618 0.6626 0.00924 0.981 0.005
Quercetin-3-O-arabinofuranoside 433.0731 0.7625 −0.01439 0.997 0.0025
Quercetin 3-O-rhamnoside 447.0920 0.9010 −0.02547 0.997 0.001
Quercetin-3-O-galactoside 463.0884 0.5151 −0.02053 0.996 0.0025
2-hydroxybenzoic acid 137.0243 1.1470 −0.13480 0.998 0.25
3-hydroxybenzoic acid 137.0231 0.1113 −0.01402 0.996 0.05
4-hydroxybenzoic acid 137.0232 0.1204 −0.04054 0.999 1
2,3-dihydroxybenzoic acid 153.0201 1.2380 −1.89800 0.984 1.5
2,5-dihydroxybenzoic acid 153.0194 0.2438 0.67780 0.998 5
2,4-dihydroxybenzoic acid 153.0175 0.3176 −0.33540 0.989 1.5
3-(4-hydroxyphenyl)-propionic acid 165.0561 0.0048 0.00106 0.999 0.25
3,4-dihydroxyphenylacetic acid 167.0349 0.0228 0.05486 0.981 1.5
Hippuric acid 178.0509 0.3032 120.80000 0.993 1
3,4-dihydroxyhydrocinnamic acid 181.0506 0.2474 0.37710 0.997 0.25
p-Hydroxyhippuric acid 194.0450 0.2756 10.42000 0.995 1
m-Hydroxyhippuric acid 194.0446 0.3605 −2.94400 0.991 1
o-Hydroxyhippuric acid 194.0461 0.6801 −4.23000 0.996 1
2-methylhippuric acid 192.0670 0.7954 3.60500 0.999 1
Quinic acid 191.0554 0.01012 0.0097 0.999 0.05
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone 207.0666 0.2411 −0.47450 0.999 0.1
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performed by considering the following parameters: accurate mass,
isotopic pattern, MS/MS fragments and the retention time. In more
details for each of the compound listed in the database, the SIC was
reconstituted setting as filter ion the m/z calculated for the target
compound; when a peak with the same RT of the targeted compound
was found, the m/z of the parent ion, the isotopic pattern and MS/MS
data were retrieved and compared with that of the standard. For some
cranberry components (gallic acid, kaempferol, quercetin, syringetin,
quercetin-3-O-arabinofuranoside, quercetin 3-O-rhamnoside and quer-
cetin-3-O-galactoside) the intensity of the parent compound was not
intense enough to perform CID experiments and their identity was
confirmed by comparing the RT and isotopic pattern with those of
genuine standards.
Tables 5 and 6 report the compounds and metabolites identified by
using such an approach and setting the ion source in negative ion mode.
Specifically, the identification of metabolites reported in Table 5 was
confirmed by pure standards, while metabolites listed in Table 6 were
putatively identified on the base of the accurate mass, isotopic pattern
and, when present, fragmentation pattern. Analyses were also carried
out in positive ion mode but no additional components were detected,
nor were anthocyanins, which are characterized by an high response in
such a polarity mode. The lack of detection of anthocyanins can be
explained by considering their biotransformation mediated by the co-
lonic microflora into small phenolic compounds, such as protocatechuic
acid, phloroglucinaldehyde, ferulic acid, syringic acid, gallic acid, caf-
feic acid and vanillic acid [31–33], some of which were detected in the
urine.
Some flavonols were found as well as some of their glycosylated
forms such as kaempferol, quercetin and traces of its glycosides
(quercetin-3-O-arabinofuranoside, quercetin-3-O-rhamnoside and
quercetin-3-O-galactoside), syringetin and traces of isorhamnetin-3-O-
arabinopyranoside. The low abundance of the glycosylated forms can
be explained by considering the enzymatic hydrolysis into the corre-
sponding aglycones mediated by cellular and bacterial β-glucosidases
and occurring in the intestine [34]. The aglycones can be transformed
by microbiota in the intestinal tract into phenolic acids by C-ring
cleavage and/or can undergo phase-II metabolism (i.e. glucuronida-
tion) or methylation [35]. Metabolic studies performed on quercetin
(the most representative flavonol) and related glycoside in the intestine
showed that the main metabolites are represented by hydro-
xyphenylacetic acid catabolites [36,37]. In fact, 3,4-dihydrox-
yphenylacetic acid was found in urine as possible metabolite of flavo-
nols deriving from intestinal microbiota metabolism.
Proanthocyanidins present in the extract (procyanidins A-type and
B-type) were not detected in urine in the present study. Results from
previous studies on this class of polyphenols are quite controversial, in
particular concerning procyanidin A2, to which several studies attrib-
uted the activity of cranberry products in UTI prevention. In most cases
[15–19], as in the present study, PACs were not detected in human
urine while two works reported PACs in human urine: one work was
performed on men and postmenopausal women of 50–70 years who
took a single dose of 237 mL of cranberry juice (PACs content in the
juice was not reported) [20]; in the second study, performed by the
same research group, five young women (20–30 years) consumed
237 mL/day of cranberry juice (140 mg of PACs) according to a weekly
schedule for 7 weeks [21]. The results that they obtained showed very
low levels of PAC-A2 quantified in human urine (CMAX = 24 ng/mg
creatinine) and they concluded that PAC-A2 cannot be used as bio-
marker of cranberry intake since there was no correlation with the
amount of juice consumed. Taking into consideration all these results, it
is commonly accepted that PACs have a very low bioavailability, which
decreases as the degree of their polymerization increases [38]. More-
over, it is reported that human microbiota degrades PACs in the colon
into phenolic compounds: phenylacetic acids and phenylpropionic acids
as metabolites of procyanidins A2, B2, catechin and epicatechin; for
procyanidin B2, catechin and epicatechin, valerolactones and valeric
acids derivatives have also been reported [39,40]. Although in the
present paper the valerolactones origin has not been investigated, we
can suggest they come from a microbiota-based transformation of
cranberry catechin/epicatechin/PACs. This assumption is supported by
independent researchers showing the catechin/epicatechin/PACs bio-
transformation to valerolactones is driven by gut microbiota. In parti-
cular, a metabolome study based on [2-14C] (−)-epicatechin in humans
showed valerolactones as epicatechin metabolites [41]. Moreover, the
bacteria Eggerthella lenta and Flavonifractor plautii were identified as
responsible for catechin/epicatechin degradation to valerolactone de-
rivatives by M. Kutschera et al. [42]. Li et al. described phenyl-valer-
olactones as the main tea catechin metabolites produced by gut mi-
croorganisms and detected in human urine and blood [43]. A gamma
valerolactone was identified by Appeldoorn M.M. et al. as a main me-
tabolite of procyanidin dimer metabolized by human microbiota [44].
Valerolactones were also detected in human urine by Ottaviani et al.
after the consumption of flavanols and PACs [45].
In the present study, the following metabolites deriving from phe-
nylpropionic acids [46] were detected: 3,4-dihydroxyphenylacetic
acid, 3-(4-hydroxyphenyl)-propionic acid, dihydroxybenzoic acids,
Table 2
Anthocyanins composition in Anthocran®.
Name RT (min) [M]+ Fragments
Anthocyanins
Cyanidin 19 287.0556 259 + 255 + 251 + 245 + 242 + 125
Peonidin 24 301.0712 268 + 258 + 230 + 177 + 151
Cyanidin-3-O-arabinoside 6.2 419.0978 287
Peonidin-3-O-arabinoside 10 433.1135 301
Cyanidin-3-O-galactoside 4.2 449.1084 287
Cyanidin-3-O-glucoside 4.6 449.1084 287
Petunidin-3-O-arabinoside 5 449.1084 317
Peonidin-3-O-galactoside 7.3 463.1240 301
Peonidin 3-O-glucoside 7.6 463.1240 301
Malvidin-3-O-galactoside 8 493.1346 331
Malvidin-3-O-glucoside 8.4 493.1346 331
Table 3
Phenolic acids in Anthocran®.
Name RT (min) [M−H]− Fragments
Phenolic acids
Benzoic acid 8.3 121.0290 77
Protocatechuic acid 4 153.0188 109
p-Coumaric acid 13.6 163.0395 119
Gallic acid 2.5 169.0137 125
Caffeic acid 7.9 179.0344 135
Ferulic acid 4.9 193.0501 149 + 134
Sinapinic acid 6.2 223.0607 179 + 164 + 149 + 135
Caffeoyl glucose 5 341.0873 179 + 135
Chlorogenic acid 6 353.0873 191 + 179 + 161
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hydroxybenzoic acid and hydroxyhippuric acids, which presence can be
related to PACs metabolism.
Phenolic acids represent the main class of identified polyphenols:
protocatechuic acid, p-coumaric acid, gallic acid and sinapinic acid
were found to be already present in the extract, but they can also derive
from the metabolism of other polyphenols as mentioned above; 3,4-
dihydroxyhydrocinnamic acid, dihydroxyhydrocinnamic acid-3-O-
glucuronide and 3-(4-hydroxyphenyl)-propionic acid can derive from
the metabolism of PACs, chlorogenic acid or anthocyanins [17,39,46],
while hydroxybenzoic acid, dihydroxybenzoic acids, hippuric acid and
hydroxyhippuric acids can derive from the metabolism of all the other
flavonoid components [46]. Catechol and pyrogallol derivatives, such
as 4-methylcatechol-O-sulphate and pyrogallol-O-2-sulphate that we
identified, can be generated from phenolic acids or anthocyanins [46].
Table 5
Cranberry components and metabolites identified using the targeted analysis.
Metabolite identification RT (min) Calculated [M−H]− Observed [M−H]− MS/MS fragments Delta ppm
Protocatechuic acid 4.1 153.0188 153.0189 109 −0.588
p-Coumaric acid 14.1 163.0395 163.0408 119 −8.035
Gallic acid 2.5 169.0137 169.0146 – −5.325
Sinapinic acid 19.4 223.0607 223.0608 179 + 164 + 149 −0.717
Kaempferol 55 285.0399 285.0407 – −2.877
Quercetin 48.9 301.0348 301.0353 – −1.395
Syringetin 55.8 345.0610 345.0618 – −2.289
Quercetin-3-O-arabinofuranoside 28.5 433.0771 433.0731 – 9.306
Quercetin 3-O-rhamnoside 30.6 447.0928 447.0920 – 1.789
Quercetin-3-O-galactoside 21.6 463.0877 463.0884 – −1.684
2-hydroxybenzoic acid 24.2 137.0239 137.0243 93 −3.065
3-hydroxybenzoic acid 8.9 137.0239 137.0231 – 5.984
4-hydroxybenzoic acid 6.6 137.0239 137.0232 93 4.671
2,3-dihydroxybenzoic acid 9.1 153.0187 153.0201 109 −8.561
2,5-dihydroxybenzoic acid 6.8 153.0187 153.0194 109 −3.856
2,4-dihydroxybenzoic acid 8.6 153.0187 153.0175 109 8.169
3-(4-hydroxyphenyl)-propionic acid 12.1 165.0552 165.0561 – −5.816
3,4-dihydroxyphenylacetic acid 4.5 167.0344 167.0349 – −2.574
Hippuric acid 8.2 178.0504 178.0509 134 −2.640
3,4-dihydroxyhydrocinnamic acid 7.1 181.0499 181.0506 137 + 121 −3.811
p-Hydroxyhippuric acid 3.6 194.0456 194.0450 150 + 100 + 93 3.401
m-Hydroxyhippuric acid 4.5 194.0456 194.0446 150 + 100 + 93 5.256
o-Hydroxyhippuric acid (salicyluric acid) 14.1 194.0456 194.0461 150 + 100 + 93 −2.628
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone 12 207.0657 207.0659 163 + 122 + 109 −0.821
Table 6
Metabolites putatively identified using the targeted analysis.
Metabolite putative identification RT (min) Calculated [M−H]− Observed [M−H]− MS/MS fragments Delta ppm
Isorhamnetin-3-O-arabinopyranoside 41 447.0927 447.0954 – −5.882
4-methylcatechol-O-sulphate 9.7 203.0014 203.0021 123 −3.300
Pyrogallol-O-2-sulphate 3.9 204.9807 204.9814 125 −3.269
Vanillic acid-4-O-sulphate 4.2 246.9912 246.9918 167 −2.105
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-4′-O-sulphate 9.5 287.0225 287.0236 207 −3.658
Dihydroxyhydrocinnamic acid-3-O-glucuronide 9.5 357.0821 357.0827 181 + 137 −1.484
Fig. 2. Searching ions in untargeted analysis –
Examples of ions not present in urine before cran-
berry intake (upper panels), but present in urine
samples after the treatment (lower panels): ions at m/
z 223.0606 and m/z 207.0665 are present only after
the treatment and identified as sinapinic acid (A) and
as 5′-(3′,4′-dihydroxyphenyl)-γ-valerolactone (B),
respectively.
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Fig. 3. Compounds identification in untargeted ana-
lysis – Single ion chromatograms relative to sinapinic
acid and 5′-(3′,4′-hydroxyphenyl)-γ-valerolactone
(D) in urine sample before cranberry intake (panels A
and D, respectively) and after 10 h and 12 h from
cranberry intake (panels B and E, respectively). Peaks
with the same RT of genuine standards are only de-
tected after cranberry intake. Final confirmation of
identities was achieved by tandem MS analyses. MS/
MS spectra of sinapinic acid (C) and 5′-(3′,4′-hydro-
xyphenyl)-γ-valerolactone (F) with the predicted
structure for each fragment assigned by the
Compound Identification tool of CFM-ID.
Table 7
Metabolites identified using the untargeted analysis. *identity confirmed by pure standard.
Metabolite putative identification RT (min) Calculated
[M−H]−
Observed
[M−H]−
MS/MS fragments Delta ppm Database
3,4-dihydroxyhydrocinnamic acid* 7.1 181.0499 181.0506 137 + 121 −3.811 HMDB
Quinic acid* 1.72 191.0556 191.0554 173 + 129 1.047 HMDB
2-methylhippuric acid* 11.1 192.0661 192.0670 74 −4.894 HMDB
p-Hydroxyhippuric acid* 3.6 194.0456 194.0450 150 + 100 + 93 3.401 HMDB
m-Hydroxyhippuric acid* 4.5 194.0456 194.0446 150 + 100 + 93 5.256 HMDB
o-Hydroxyhippuric acid (salicyluric acid)* 14.1 194.0456 194.0461 150 + 100 + 93 −2.628 HMDB
Sinapinic acid* 19.4 223.0607 223.0608 179 + 164 + 149 −0.717 HMDB
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone* 12 207.0657 207.0659 163 + 122 + 109 −0.821 HMDB
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-O-
sulphate
9.5 287.0225 287.0236 207 −3.658 HMDB
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-4′-O-
sulphate
10.2 287.0225 287.0233 207 −2.474 HMDB
5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone-3′-O-
sulphate
6.6 303.0175 303.0167 223 2.442 HMDB
4-Hydroxy-5-(dihydroxyphenyl)-valeric acid-O-
sulphate
6.4 305.0331 305.0341 225 −3.213 HMDB
Dihydroxyhydrocinnamic acid-3-O-glucuronide 9.5 357.0821 357.0826 181 + 137 −1.484 HMDB
Salicyluric glucuronide 9.2 370.0774 370.0783 194 + 150 −2.513 PubChem
3-O-Methylcatechin-sulphate 12.3 383.0437 383.0442 303 + 285 + 259 + 244 + 217 + 137 −1.279 PubChem
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′-O-
glucuronide
8.1 383.0978 383.0981 207 −0.783 HMDB
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-4′-O-
glucuronide
9.4 383.0978 383.0982 207 −1.044 HMDB
Sinapinic glucuronide 6.8 399.0928 399.0931 223 −0.877 HMDB
5-(3′,4′-dihydroxyphenyl)-γ-valerolactone
sulphoglucuronide
4.6 463.0546 463.0548 383/287/207 −0.302 [47]
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3.4. Untargeted analysis of human urine after cranberry extract intake
As described in the method session, the untargeted approach con-
sists of searching for all the ions present in the urine samples collected
after cranberry consumption that were not present or present at in-
tensity relative to noise less than 5*102 counts in the pre-treatment
sample. The analysis was performed using the negative ion mode be-
cause all the compounds identified using the targeted analysis were
mainly detected in this polarity mode. The unidentified compounds, or
those recognized as coming from the human basal metabolism (e.g.
amino acids), were not included on the list. The search of ions was
performed by screening the full MS spectra acquired in negative ion
mode using a mass ranges of m/z 5 and with 10 min as acquisition time
for each sample. As an example, Fig. 2A reports the MS spectra resulting
by setting a MS range between m/z 220 and 225 and considering a time
window between 0 and 10 min and relative to urine collected before
(upper panel) and after 10 h (lower panel) the cranberry intake; Fig. 2B
reports the MS spectra resulting by setting a MS range between m/z 205
and 210 and considering a time window between 10 and 20 min and
relative to urine collected before (upper panel) and after 12 h (lower
panel) the cranberry intake. The ions at m/z 223.0606 and m/z
207.0665 are well evident only in the urine samples collected after the
cranberry administration but not before. Identification of the unknown
compounds was carried out by setting the precursor ion and the MS/MS
fragment ions as inputs in the Compound Identification tool of CFM-ID.
Fig. 3C and Fig. 3F reports the experimental MS/MS spectra used as
input for the Compound Identification tool of CFM-ID which gave si-
napinic acid and 5′-(3′,4′-dihydroxyphenyl)-γ-valerolactone as best
matched results. Final attribution was obtained by comparing RT, MS
isotopic pattern and MS/MS fragmentation with those of pure standards
(when commercially available). Fig. 3 shows the SIC chromatograms of
sinapinic acid (Fig. 3B) and 5′-(3′,4′-dihydroxyphenyl)-γ-valerolactone
(Fig. 3E) in the urine fraction in which they reached their maximum
concentration (10 h for sinapinic acid and 12 h for 5′-(3′,4′-dihydrox-
yphenyl)-γ-valerolactone), while in the control sample (Figs. 3A and
3D, respectively) they were not present.
Several metabolites were identified in the untargeted analysis as
reported in Table 7. Some of them had already been identified using the
Fig. 4. Targeted and untargeted identifications – Venn diagram reporting all of the 42 compounds identified with the targeted (blue circle) and untargeted (yellow
circle) analyses.
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targeted analysis, such as 3,4-dihydroxyhydrocinnamic acid, dihy-
droxyhydrocinnamic acid-3-O-glucuronide, sinapinic acid, the three
hydroxyhippuric acid isomers, 5-(3′,4′-dihydroxyphenyl)-γ-valer-
olactone and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-4′-O-sulphate.
Fig. 4 shows an overview of all the 42 compounds which have been
identified in the present study with the targeted (blue circle) and un-
targeted (yellow circle) analyses.
Besides quinic acid, which can derive from chlorogenic acid, and 2-
methylhippuric acid, a methyl derivative of hippuric acid, different
valerolactones and one valeric acid derivative were identified and listed
in Table 7. Among these metabolites, 5-(3′-hydroxyphenyl)-γ-valer-
olactone-4′-O-sulphate had been identified in previous studies [17,18].
Also 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone has already been re-
ported as cranberry metabolite [19]. None of the other valerolactones
here described had previously been identified in urine after cranberry
intake, although they are known as PACs metabolites [39,47].
Table 8 summarizes the overall cranberry components and meta-
bolites, including PACs and their metabolites, so far identified in human
studies, in comparison with those reported in the present study. In-
formation on the treatment (dose and PACs content of the given cran-
berry) are also summarized. As already discussed above, PACs were
detected only in two studies [20,21] and in one of these [20] the
amount of PACs in the cranberry juice was not reported. In these two
studies, phenolic acids were reported as PACs metabolites and no va-
lerolactone derivatives were detected as in the study performed by
Valentova et al. [15]. Feliciano et al. [17,18] identified several PAC
metabolites by using standards, and among these only one valer-
olactone derivative was identified, while Peron et al. [19] reported a
lower amount of metabolites but a higher number of valerolactone/
valeric acid derivatives, one of which was also detected in this study.
Hence, the untargeted approach here reported has permitted the
identification of six valerolactones/valeric acid whose presence in urine
after cranberry consumption has never been described before.
3.5. Ex-vivo inhibition of Candida albicans biofilm-formation by urine
fractions
Anthocran® (0.1 mg/mL), urine collected before administration of
Anthocran®, Anthocran™ Phytosome™ or placebo and urine fractions
collected after 1 h, 2 h, 4 h, 6 h, 10 h, 12 h and 24 h of each treatment
were tested to investigate their potential ability to reduce C. albicans
adhesion and biofilm formation on polystyrene 96-well plates.
Anthocran® 0.1 mg/mL was able to strongly reduce the adhesion and
biofilm formation (p < 0.0001) of the biofilm-producing strain
SC5314 (data not shown). Results expressed as mean ± SD of urine
fractions are reported in Fig. 5. Urine samples before (U-Pre) each
treatment were inactive, while among the seven fractions tested those
collected after 12 h the Anthocran® consumption (Fig. 5A) as well as
Anthocran™ Phytosome™ (Fig. 5B) were shown to significantly inhibit
the adhesion compared with the control (p < 0.05 and p < 0.01,
respectively for Anthocran® and Anthocran™ Phytosome™). Urine
fractions after placebo intake showed no activity at all, meaning that
diet and the cyrcadian rhythm does not influence activity. It should be
noted that the effect of Anthocran™ Phytosome™ at 12 hr superimposes
that of Anthocran®, despite the dose of Anthocran® per capsule being 1/
3 in the phytosomal preparation (12 mg PACs/capsule Anthocran™
Phytosome™ vs 36 mg PACs/capsule Anthocran®). Phytosomes are le-
cithin formulations demonstrated to enhance botanical ingredients oral
bioavailability both at preclinical and clinical levels [48–51]. The si-
milar ability to reduce C. albicans adhesion and biofilm despite the
reduced cranberry extract dose can be consequently explained by
considering an increased absorption of active principles allowed bythe
Phytosome technology. This figure can positively contribute to a more
rational and convenient modulation of clinical dosage and posology.
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3.6. Metabolite concentration in urine samples
In order to identify the cranberry components/metabolites char-
acteristic of the bioactive fractions and hence most likely responsible
for the ability to reduce C. albicans adhesion and biofilm formation, the
concentration of the available metabolites for each urinary fraction was
obtained through the quantitative analysis explained in the method
section. Concentrations of the urinary components are reported as µM
in order to allow the reassemble of the mixtures by using pure com-
pounds and confirm their activities (see below). As examples, Fig. 6
shows two compounds which reached their maximum abundance in the
active fraction and two compounds that reached this value in other
Fig. 5. Inhibition of Candida albicans biofilm forma-
tion – Biofilm biomass was assessed using the crystal
violet assay after C. albicans SC5314 strain was cul-
tured for 24 h in RPMI 1640 with/without treat-
ments. A) Activity of urine before Anthocran® intake
(U-Pre) and urinary fractions after treatment (U-1 h –
U-24 h). Biomass of untreated C. albicans biofilm was
used as control (C. albicans). B) Activity of urine
fractions (U-1 h – U-24 h) after oral intake of
Anthocran™ Phytosome™ and of urine before
Anthocran™ Phytosome™ intake (U-Pre). Untreated
C. albicans biofilm (C.albicans) was used as control. C)
Activity of urine fractions (U-1 h – U-24 h) after oral
intake of placebo (U-1 h – U-24 h). Control as de-
scribed for B). Values represent the mean of three
independent experiments, and of at least three
sample replicates. Significant differences are in-
dicated by *p < 0.05, **p < 0.01, ANOVA test.
Fig. 6. Urinary profile of some metabolites – Excretion profiles of 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (A), quercetin (B), p-coumaric acid (C) and 3,4-dihy-
droxyphenylacetic acid (D).
G. Baron, et al. Biochemical Pharmacology xxx (xxxx) xxxx
11
Ta
bl
e9
Cr
an
be
rry
co
mp
on
en
ts
an
dm
eta
bo
lit
es
me
an
(±
SD
)c
on
ce
nt
rat
ion
(µ
M)
in
ur
ine
fra
cti
on
s.
N.
D.
:n
ot
de
tec
ted
.
Na
me
Pr
e-t
rea
tm
en
t
1h
2h
4h
6h
10
h
12
h
24
h
Pr
oto
ca
tec
hu
ic
ac
id
1.2
0
±
1.0
0
7.2
4
±
3.3
1
4.9
7
±
1.5
2
10
.81
±
4.4
5
2.1
2
±
1.3
3
3.7
8
±
1.4
7
2.0
3
±
0.8
2
2.5
1
±
0.9
4
p-C
ou
ma
ric
ac
id
0.3
9
±
0.2
4
13
.11
±
8.3
0
16
.63
±
10
.27
17
.81
±
8.4
3
3.1
3
±
1.6
2
5.4
0
±
1.4
3
1.6
0
±
0.3
1
0.5
5
±
0.2
8
Ga
llic
ac
id
<
LO
Q
2.2
8
±
1.3
4
<
LO
Q
1.4
5
±
1.0
6
<
LO
Q
3.0
2
±
1.5
6
2.1
8
±
0.9
1
1.2
2
±
0.5
3
Sin
ap
ini
ca
cid
0.2
9
±
0.1
9
47
.02
±
46
.73
25
.36
±
24
.52
68
.25
±
67
.50
11
8.7
5
±
11
7.7
7
25
5.9
0
±
24
7.7
9
84
.29
±
80
.26
11
1.5
3
±
10
9.3
2
Ka
em
pfe
ro
l
N.
D.
0.0
83
±
0.0
33
0.0
4
±
0.0
3
N.
D.
N.
D.
0.0
2
±
0.0
1
0.0
4
±
0.0
3
N.
D.
Qu
erc
eti
n
<
LO
Q
0.1
08
±
0.0
36
0.1
4
±
0.0
4
0.1
5
±
0.0
1
0.1
5
±
0.0
1
0.6
3
±
0.1
9
0.6
3
±
0.2
7
0.1
8
±
0.0
1
Sy
rin
ge
tin
N.
D.
0.1
5
±
0.1
4
0.0
2
±
0.0
2
N.
D.
N.
D.
0.1
5
±
0.1
4
0.0
3
±
0.0
2
N.
D.
Qu
erc
eti
n-3
-O
-ar
ab
ino
fur
an
os
ide
N.
D.
0.0
1
±
0.0
1
0.0
3
±
0.0
1
0.0
1
±
0.0
1
0.0
1
±
0.0
1
0.0
2
±
0.0
1
0.0
1
±
0.0
1
N.
D.
Qu
erc
eti
n
3-O
-rh
am
no
sid
e
N.
D.
0.0
4
±
0.0
2
0.0
3
±
0.0
1
0.0
2
±
0.0
1
N.
D.
N.
D.
N.
D.
N.
D.
Qu
erc
eti
n-3
-O
-ga
lac
tos
ide
N.
D.
N.
D.
0.0
2
±
0.1
2
0.0
8
±
0.0
6
N.
D.
N.
D.
0.0
1
±
0.0
1
N.
D.
2-h
yd
ro
xy
be
nz
oic
ac
id
<
LO
Q
0.2
6
±
0.1
1
<
LO
Q
<
LO
Q
<
LO
Q
0.8
5
±
0.4
4
0.3
6
±
0.1
5
0.3
8
±
0.1
8
3-h
yd
ro
xy
be
nz
oic
ac
id
N.
D.
N.
D.
N.
D.
1.1
9
±
1.0
7
1.3
1
±
1.1
5
N.
D.
N.
D.
N.
D.
4-h
yd
ro
xy
be
nz
oic
ac
id
4.5
8
±
2.7
3
23
.84
±
14
.69
18
.10
±
9.9
0
13
.91
±
8.3
5
2.5
1
±
1.4
4
7.7
4
±
4.6
5
3.7
1
±
2.0
7
4.2
9
±
3.7
5
2,3
-di
hy
dr
ox
yb
en
zo
ic
ac
id
<
LO
Q
2.4
4
±
0.5
3
2.2
0
±
1.1
6
2.5
0
±
0.8
0
1.6
2
±
0.6
9
2.9
9
±
1.2
3
1.6
2
±
0.6
4
<
LO
Q
2,5
-di
hy
dr
ox
yb
en
zo
ic
ac
id
<
LO
Q
10
.48
±
4.2
0
<
LO
Q
<
LO
Q
<
LO
Q
14
.56
±
5.4
0
5.0
7
±
1.3
7
6.0
4
±
2.0
3
2,4
-di
hy
dr
ox
yb
en
zo
ic
ac
id
<
LO
Q
1.5
1
±
1.1
8
3.5
8
±
2.4
0
4.6
1
±
3.4
4
<
LO
Q
3.4
0
±
3.0
4
1.5
5
±
1.2
2
2.8
8
±
2.5
7
3-(
4-h
yd
ro
xy
ph
en
yl)
-pr
op
ion
ic
ac
id
0.5
8
±
0.5
5
25
.79
±
19
.77
4.2
2
±
2.8
5
20
.23
±
7.9
2
17
.74
±
16
.76
4.1
0
±
1.9
1
1.1
8
±
0.6
4
N.
D.
3,4
-di
hy
dr
ox
yp
he
ny
lac
eti
ca
cid
N.
D.
N.
D.
N.
D.
1.4
9
±
1.2
4
3.1
0
±
2.0
6
9.3
6
±
6.3
6
3.8
5
±
2.7
0
4.0
6
±
2.8
5
Hi
pp
ur
ic
ac
id
66
6.1
5
±
29
.07
23
0.1
2
±
19
.82
55
7.7
2
±
26
.45
40
9.8
2
±
17
.03
65
6.4
6
±
24
.06
53
1.8
4
±
68
.23
19
2.9
1
±
31
.13
64
8.5
2
±
27
.88
3,4
-di
hy
dr
ox
yh
yd
ro
cin
na
mi
ca
cid
0.4
5
±
0.4
0
4.3
9
±
4.0
3
2.9
9
±
2.6
9
3.2
4
±
2.4
3
2.5
0
±
2.4
5
7.1
5
±
4.8
9
4.4
6
±
2.0
5
5.0
8
±
2.1
2
p-H
yd
ro
xy
hip
pu
ric
ac
id
47
.16
±
12
.68
1.4
8
±
0.4
9
14
.14
±
3.1
5
30
.64
±
4.5
3
59
.89
±
14
.55
9.0
4
±
4.1
3
<
LO
Q
46
.19
±
4.3
4
m-
Hy
dr
ox
yh
ipp
ur
ic
ac
id
24
.80
±
13
.21
21
.91
±
3.3
7
37
.88
±
12
.61
25
.57
±
8.1
5
43
.60
±
10
.17
32
.36
±
3.5
4
29
.03
±
13
.24
24
.89
±
3.7
4
o-H
yd
ro
xy
hip
pu
ric
ac
id
36
.65
±
8.2
1
10
.84
±
1.1
4
8.4
4
±
3.3
1
7.8
6
±
2.6
8
17
.99
±
3.4
2
19
.79
±
1.2
0
13
.32
±
2.7
8
27
.48
±
3.3
0
2-m
eth
ylh
ipp
ur
ic
ac
id
N.
D.
2.0
70
±
1.1
1
4.8
5
±
0.9
7
<
LO
Q
N.
D.
N.
D.
N.
D.
N.
D.
Qu
ini
ca
cid
5.4
9
±
3.8
0
12
.71
±
8.0
2
6.4
2
±
4.3
8
10
.15
±
8.2
9
9.2
3
±
2.2
6
17
.36
±
9.8
2
14
.74
±
7.3
2
8.5
0
±
4.9
2
5-(
3′,
4′-
dih
yd
ro
xy
ph
en
yl)
-γ-
va
ler
ola
cto
ne
N.
D.
88
.34
±
61
.63
41
.51
±
15
.10
26
.40
±
14
.03
13
.83
±
11
.89
23
8.2
2
±
12
9.4
6
24
5.2
4
±
14
3.5
9
3.8
3
±
2.0
8
G. Baron, et al. Biochemical Pharmacology xxx (xxxx) xxxx
12
urine fractions: Fig. 6A and B are relative to 5-(3′,4′-dihydroxyphenyl)-
γ-valerolactone and quercetin, respectively, whose TMAX was 12 h;
Fig. 6C is relative to p-coumaric acid, with a TMAX reached after 4 h;
Fig. 6D shows the excretion profile of 3,4-dihydroxyphenylacetic acid
(TMAX = 10 h). Table 9 shows the mean cranberry metabolite con-
centrations (µM) in the control and in the urine fractions after cran-
berry intake.
The mixture of the active urine fractions (12 h) and of two inactive
fractions (1 h and 6 h) were then reassembled by using available
standards dissolved in RPMI and tested on C. albicans. The 12 h mixture
was found to significantly reduce adhesion while the other two mix-
tures were inactive, thus confirming the results of the ex-vivo urine
samples (Fig. 7). It is important to underline that the 12 h reconstituted
mixture only contained one of the 8 valerolactone derivatives identified
(namely, 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone) due to the lack of
commercial availability of valerolactone standards (their synthesis is
on-going in our laboratories). Hence if the bioactivity is related to this
class of compounds, as expected, a greater activity could be obtained by
integrating the reconstituted mixture with the other seven valer-
olactones.
The antiadhesive properties of cranberry, both in vitro and in vivo,
have long been reported [52–55] mainly with regard to E. coli, which is
the principal uropathogen that causes UTIs. An in vitro study showed
that cranberry PACs prevent C. albicans biofilm formation in artificial
urine [56]. In the present work, we demonstrate for the first time that
cranberry extract as well as some urine fractions, collected after one
week of cranberry administration, reduce both C. albicans adhesion and
biofilm biomass. Since 12 h urine fractions were the most active, we
focused our attention on the components that reached their highest
concentration at this time point. The components found to have the
highest concentration in this urine fraction are quercetin and 5-(3′,4′-
dihydroxyphenyl)-γ-valerolactone. A recent in vitro study [57] demon-
strates that valerolactone derivatives display anti-adhesive activity
against E. coli, confirming that the in vivo activity is due to PACs me-
tabolites rather than intact PACs. Moreover, quercetin was reported to
have in vitro anti-adhesive properties on E. coli [58]. However, the ac-
tivity could derive not only by a single component but from a synergy of
all the metabolites present in that mixture, thus explaining the possible
activity of cranberry as a phytocomplex. In fact, many components
present in the mixture showed an activity against biofilm formation or
anti-adhesive properties against E. coli, like protocatechuic acid, 3,4-
dihydroxyphenylacetic acid and 2-hydroxybenzoic acid [59–61].
In conclusion, the HR-MS method developed allowed the identifi-
cation of several cranberry components and metabolites in human urine
after a highly standardized cranberry extract consumption which has
been found to be effective in human studies. PACs were not detected as
reported by previous studies, but several metabolites deriving from
their catabolism presumably operated by the gut microflora and hereto
not found in vivo were identified. The crude extract and the urine
fraction collected at 12 h after cranberry intake were found to be active
against C. albicans adhesion ex-vivo. The known metabolite of PACs, 5-
(3′,4′-dihydroxyphenyl)-γ-valerolactone was identified as the most
abundant metabolite (245 µM) in the bioactive urine fraction. To our
knowledge, this is the first work which demonstrates an ex-vivo in-
hibition of C. albicans adhesion by human urine after cranberry intake.
As a future perspective, as soon as all the identified compounds peaking
at 12 h will be available (the synthesis of valerolactones derivatives is
on-going) their activity against C. albicans will be evaluated, with a
particular interest focused on valerolactone derivatives which represent
the most abundant metabolites in urine after cranberry intake.
Furthermore, in order to understand whether a synergistic action is
involved, compounds will be tested in pure form or in mixture.
A further interesting result of our study derives from the use of the
lecithin formulation of the cranberry extract which has shown to
markedly increase oral bioavailability and organ target accessibility of
cranberry active principles. A clinical study in catheterized subjects is
on-going to confirm the effectiveness of Anthocran™ Phytosome™.
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